کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2112742 1084419 2014 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models
چکیده انگلیسی

The dual PI3K–mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Letters - Volume 343, Issue 1, 1 February 2014, Pages 24–32
نویسندگان
, , , , , , , , , , , , ,